The US Federal Trade Commission intervened in Sage Chemical, Inc.’s antitrust suit against Supernus Pharmaceuticals, Inc., criticizing Supernus’ alleged strategies to block entry of a generic version of its Apokyn (apomorphine hydrochloride injection) by leveraging control over the Apokyn pen injector and rebutting Supernus’s defense.
Sage is in an unusual position as it must have access to the auto injector pen used to deliver Apokyn...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?